key: cord-0955996-44iwdu7u
authors: Treggiari, Davide; Piubelli, Chiara; Caldrer, Sara; Mistretta, Manuela; Ragusa, Andrea; Orza, Pierantonio; Pajola, Barbara; Piccoli, Donatella; Conti, Antonio; Lorenzi, Carlo; Serafini, Valentina; Boni, Marco; Perandin, Francesca
title: SARS‐CoV‐2 rapid antigen test in comparison to RT‐PCR targeting different genes: A real‐life evaluation among unselected patients in a regional hospital of Italy
date: 2021-10-14
journal: J Med Virol
DOI: 10.1002/jmv.27378
sha: d948e8f028de503405723f7eb96fb2439b083d85
doc_id: 955996
cord_uid: 44iwdu7u

We assessed the performance of the Panbio rapid antigen detection (RAD) test for the detection of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and we compared it with the routine reverse transcriptase‐polymerase chain reaction (RT‐PCR)‐based molecular test in a population of 4167 unselected patients admitted to IRCCS Sacro Cuore Don Calabria Hospital. Analysis stratified by cycling threshold (C (t)) value of SARS‐CoV‐2 gene targets indicated that antigen (Ag)‐positive C (t) values were significantly lower compared to Ag‐negative values (p < 0.0001). Overall, we found discordance in 140, tested negative by RAD and positive by RT‐PCR, and in 4 resulted positive by RAD and negative by RT‐PCR. RAD test achieved a sensitivity and specificity of 66.82% and 99.89%, respectively. The positive predictive value was shown to be 97.87% while the negative predictive value was shown to be 97.62%. In our context, the RAD test showed a reliable diagnostic response in subjects that displayed high C (t) values, corresponding to high viral load, while low ability was displayed to identify positive cases with medium‐low C (t) values, thus presenting low viral load and where confirmatory RT‐PCR was needed. Our finding supports the use of the RAD test in real‐life settings where a high volume of swabs is being processed but with caution when interpreting a positive test result in a low prevalence setting.

Identification of people infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an essential prerequisite for controlling the pandemic spreading. Reverse transcriptasepolymerase chain reaction (RT-PCR) molecular represents the gold standard for the diagnosis of viral infection, it is very sensitive and accurate and remains the reference method for diagnosing coronavirus disease 2019. However, nucleotide-based testing of viral RNA is expensive time-consuming, and required specialized laboratory settings, in terms of personnel and instrumentation.

Coronavirus rapid antigen detection (RAD) tests, with the appropriate application in the context of the pandemic, may contribute to the overall diagnostic capacity, offering benefits in terms of response times, and costs for the healthcare system, especially in situations in which the possibility of performing a molecular test on nasopharyngeal swab could be limited. 1 The use of RAD can be recommended to test people, regardless of symptoms, when a high positive percentage is expected, for example, that approximates or exceed 10%. 2, 3 Despite the lower sensitivity (Sn) when compared with the molecular assays, the RAD is a potentially highly valuable test in terms of surveillance, to track and prevent the spread of infection. 2 The antigen (Ag) tests, based on the immunochromatographic principle, essentially detect SARS CoV-2 nucleocapsid protein (N), they are performed at or near the place where a specimen is collected, and they provide results onsite within few minutes. However, due to the different methods applied, RAD tests tend to be less sensitive than RT-PCR tests, being more prone to false-negative results, therefore every suspected case must be confirmed by a molecular test.

Information on the performance of RAD tests is limited and the Sn of first-generation Ag is overall low. 3 

The study was conducted in accordance with the European 

Descriptive statistics were generated to define the study population.

Kruskal-Wallis one-way analysis of variance (ANOVA) was applied for comparisons between three or more groups of gene targets.

A p < 0.05 was defined as the level of significance. Agreement between RAD assay and RT-PCR tests was assessed using Cohen's κ statistics. Graphpad (GraphPad Software) and MedCalc (MedCalc Software) were used to perform statistical analyses.

For this study, we analyzed the data collected from 4167 nasopharyngeal swabs. The demographic characteristics for all patients studied are summarized in Table 1 . There was no difference in the proportion of females compared to males (50.2% and 49.8%, respectively). The majority of the samples were from the Emergency Room, accounting for 65.19%.

To evaluate the "on-field" diagnostic performance of the RAD test in the discriminating presence or absence of SARS-CoV-2, we calcu- showing median (horizontal line), boxes representing the 25th to 75th percentiles, whiskers representing minimum and maximum values. ***p < 0.001, **p < 0.001 was determined by one-way ANOVA. ANOVA, analysis of variance; RAD, rapid antigen detection; RT-PCR, reverse transcriptase-polymerase chain reaction F I G U R E 2 Comparison of C t values of SARS-CoV-2 RT-PCR gene targets according to RAD result. Each dot plot represents an individual C t value. One-way ANOVA was performed (***p < 0.0001). ANOVA, analysis of variance; RAD, rapid antigen detection; RT-PCR, reverse transcriptase-polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 some discrepancies between the molecular and the RAD test: 3.39% of the false-negative results were observed for high C t values, whereas we found concordance between RAD and RT-PCR test at medium-lower C t , reflecting the ability of the RAD test to detect better high viral load in presumably symptomatic subjects. This was successfully established as described by Platten et al., 6 demonstrating that RAD is frequently negative in PCR positive samples with C t values above 24-28. A further discrepancy was observed in 0.09% of swabs that resulted positive to the Ag test but negative by RT-PCR. A partial reason for this discordance might be due to errors that might have affected the preanalytical phase (e.g., sample collection) or the data collection (e.g., subjective RAD reading).

Overall, the RAD test revealed a moderate Sn (66.82%) and good Sp (99.89%) in our study. The manufacturer reported a Sn of 98.1% (95% CI, 93.2%-99.8%) and a Sp of 99.8% (95% CI, 98.6%-100.0%) when performed in symptomatic subjects (n = 104), while when tested in asymptomatic subjects (n = 483), the Sn was lowered to 66.0% (95% CI, 51.2%-78.8%). Literature data are wide-ranging in terms of overall accuracy for this test. Studies conducted on pure symptomatic patients reported an Sn varying from 87% to 71%, 7-9 whereas a study conducted on asymptomatic patients reported a very low Sn for this test (55.3%). 10 Our data, collected from a mixed population of symptomatic and asymptomatic subjects, is in line with the other two studies reporting an overall Sn of about 60%-70% in heterogeneous patients. 11, 12 Anyhow, the results showed a lower Sn as compared to The main limitation of the present study is the lack of clinical data since our finding came from a large cohort of subjects tested irrespective of clinical presentation; therefore, we cannot correlate the Sn of the Ag test with the onset of symptoms. Secondarily, despite RAD tests were meticulously performed at the point of care following the manufacturer's instruction, many variables (e.g., subjectivity in reading) may have influenced the result of the test.

Moreover, since the data reported here come from real daily activity, it was not possible to repeat the Ag test or the molecular tests for discordant cases and the RT-PCR result was considered for the diagnosis. Collectively, notwithstanding these limitations, our finding supports the use of RAD test in high prevalence settings, where a high volume of swabs is being processed, and, hence, a first prompt result of infectivity is essential, improving clinical manage- 

Evaluation of the Panbio COVID-19 rapid antigen detection test device for the screening of patients with COVID-19

Rethinking Covid-19 test sensitivity-a strategy for containment

Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection

Options for the use of rapid antigen tests for COVID-19 in the EU/EEA and the UK

World Health Organization. Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays interim guidance

SARS-CoV-2, CT-values, and infectivity-conclusions to be drawn from side observations

Evaluation of the accuracy and ease-of-use of Abbott PanBio-a WHO emergency use listed, rapid, antigen-detecting point-of-care diagnostic test for SARS-CoV-2. medRxiv

Multicenter evaluation of the panbio TM COVID-19 rapid antigen-detection test for the diagnosis of SARS CoV-2 infection

Real-life validation of the Panbio™ COVID-19 antigen rapid test (Abbott) in community-dwelling subjects with symptoms of potential SARS-CoV-2 infection

Diagnostic performance of a SARS-CoV-2 rapid antigen test in a large, Norwegian cohort

Evaluation of the Panbio™ rapid antigen test for SARS-CoV-2 in primary health care centers and test sites

Nasopharyngeal Panbio COVID-19 antigen performed at point-of-care has a high sensitivity in symptomatic and asymptomatic patients with higher risk for transmission and older age

False positive rapid antigen tests for SARS-CoV-2 in the real-world and their economic burden

Frontline screening for SARS-CoV-2 infection at emergency department admission by third generation rapid antigen test: can we spare RT-qPCR?

Emergence of N antigen SARS-CoV-2 genetic variants escaping detection of antigenic tests. medRxiv

SARS-CoV-2 rapid antigen test in comparison to RT-PCR targeting different genes: a real-life evaluation among unselected patients in a regional hospital of Italy